Anemia

Oxygen-regulated erythropoietin gene therapy reverses chronic anemia

Published in Gene Therapy Weekly, December 12th, 2002

by Sonia Nichols, senior medical writer - Researchers at Oxford Biomedica in England announced the development of an oxygen-regulated erythropoietin gene therapy that may correct blood cell production in people with chronic anemia.

Erythropoietin (Epo) regulates the manufacture of red blood cells. Doctors often prescribe recombinant erythropoietin to accommodate its shortfall in chronically anemic patients. Now, a team at Oxford Biomedica has developed an oxygen-responsive erythropoietin gene therapy that corrects hemotocrit levels in research animals and which may be better than standard recombinant therapy.

They evaluated its efficacy in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry